Since the introduction of adjuvant trastuzumab anti-HER2 therapy and the subsequent development of several further anti- HER2 agents, accurate identification of patients with HER2 positive breast carcinoma has been essential to ensure appropriate personalised management of their disease [1]. The gene discussed is ERBB2; the disease is breast carcinoma.